New product: Bimzelx (bimekizumab) solution for injection
Bimekizumab is a humanised IgG1/κ monoclonal antibody that selectively binds with high affinity to IL-17A, IL-17F and IL-17AF cytokines. It is licensed for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Source:
electronic Medicines compendium
SPS commentary:
NICE has published guidance (TA723) recommending bimekizumab as an option for treating plaque psoriasis in adults, if disease is severe (PASI ≥ and DLQI >10) and has not responded to other systemic treatments, or these options are contraindicated or not tolerated, and it is provided under the commercial agreement.